The REMAP-CAP trial recently detected mortality benefit from tocilizumab in patients with COVID-19. However, several other RCTs have failed to find substantial benefit from tocilizumab. This begs the question: Has REMAP-CAP discovered a uniquely beneficial way to use tocilizumab, or is this simply a statistical outlier? evidence roundup: RCTs on tocilizumab Let’s review the trials. … Continue reading PulmCrit – Six RCTs to answer one question: what is the role of tocilizumab in COVID-19?
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed